Knockdown of EPSTI1 alleviates lipopolysaccharide-induced inflammatory injury through regulation of NF-κB signaling in a cellular pneumonia model.

BACKGROUND: Although early diagnosis, antibiotic therapies, corticosteroid application, and health care services are conventional managements for pneumonia, antibiotic resistance and adverse reactions remain as limitations for pneumonia treatment. OBJECTIVES: The study attempted to evaluate the potential role of EPSTI1 against pneumonia and reveal its underlying mechanism. METHODS: Lipopolysaccharide (LPS) (5, 10, and 20 µg/mL) was applied in WI-38 cells to establish the in vitro pneumonia model. Knockdown of epithelial-stromal interaction 1 (EPSTI1) was performed by transfection with EPSTI1 siRNA (siEPSTI1) into LPS-treated cells. Cell Counting Kit-8 assays were implemented to measure cell viability, and apoptotic cells were detected using flow cytometry. Interleukin-1ß (IL-1ß), IL-6, and tumor necrosis factor-α (TNF-α) were quantified using enzyme-linked immunosorbent assay (ELISA). Immunoblotting and quantitative real-time polymerase chain reaction (qRT-PCR) were conducted to quantify EPSTI1 expression, and proteins related to nuclear factor κ-light-chain-enhancer of activated B cell (NF-κB) signaling, including p-p65, p65, p-IκBα, and IκBα. RESULTS: EPSTI1 was highly expressed in LPS-treated WI-38 cells. Cell apoptosis was promoted, and cell viability was inhibited after being exposed to LPS. Besides, IL-1ß, IL-6, and TNF-α were dramatically upregulated. Knockdown of EPSTI1 restored cell viability, inhibited cell apoptosis, and attenuated expressions of proinflammatory factors. Additionally, knockdown of EPSTI1 visibly decreased the increased ratios of p-p65/p65 and p-IκBα/IκBα induced by LPS. Knockdown of EPSTI1 alleviated inflammatory injury through the inactivation of the NF-κB pathway. CONCLUSIONS: These results provided promising management in preventing pneumonia in patients.

Effect of glucocorticoid therapy on long-term growth and development of children with bronchiolitis. / ç³–çš®è´¨æ¿€ç´ æ²»ç–—å¯¹ç»†æ”¯æ°”ç®¡ç‚Žæ‚£å„¿é•¿æœŸç”Ÿé•¿å‘è‚²çš„å½±å“.

OBJECTIVES: To explore the effect of glucocorticoid therapy on the growth and development of children with bronchiolitis. METHODS: A total of 143 children with bronchiolitis who were treated with glucocorticoids from February 2017 to March 2018 were enrolled. The medical data were retrospectively collected, including height, weight, course of the disease, and diagnosis and treatment plan at initial admission. After three years of treatment, physical development indices were measured, growth and development were evaluated by Z-score, and related hematological parameters were measured, including osteocalcin, serum phosphorus, and insulin-like growth factor-1. RESULTS: As for the children with bronchiolitis, the incidence rates of growth retardation and obesity increased significantly after three years of glucocorticoid therapy (P<0.05). The children treated with glucocorticoids for ≥29 days showed a significantly higher incidence rate of obesity than those treated with glucocorticoids for <29 days (P<0.05), while nebulized glucocorticoid treatment had no effect on the growth and development (P>0.05). Compared with the children with growth retardation, the children with normal development had significantly higher levels of serum phosphorus and insulin-like growth factor-1 (P<0.05). CONCLUSIONS: Glucocorticoid therapy can adversely affect long-term growth and development in children with bronchiolitis.

Changes and significances of interleukin-6, interleukin-10 and vascular adhesion molecule-1 in children with obstructive sleep apnea-hypopnea syndrome / 中华实用儿科临床杂志

Objective To discuss the variation in serum factor IL-6,anti-inflammatory cytokine IL-10,and vascular cell adhesion molecule-1 (ICAM-1) level of children with obstructive sleep apnea-hypopnea syndrome (OSAHS) and their clinical significances.Methods One hundred and forty-two hospitalized children were divided into 2 groups:OSAHS group (47 cases) and the control group (95 cases),according to test result of polysomnography (the golden standard).The differences of IL-6,IL-10,high-sensitivity C-reactive protein (hsCRP) and ICAM-1 level between the two groups were measured and compared by using enzyme linked immunosorbent assay,and correlation analysis between IL-6,IL-10,ICAM-1 and each sleep-breathing parameter of OSAHS group was performed.The children of OSAHS group were divided into 3 groups:mild,moderate and severe group,according to the level of apnea hypopnea index(AHI).Statistical analysis was performed on the above indexes among the 3 groups.Reassessment of the children diagnosed with OSAHS was performed after 12 weeks of treatment.Results The serum levels of IL-6,ICAM-1 and hsCRP [(2.98 ± 0.27) ng/L,(391.7 ± 115.6) μg/L,(15.4 ± 4.9) mg/L] of OSAHS group were significantly higher than those of the control group[(1.67 ± 0.07) rng/L,(189.8 ± 106.4) μg/L,(2.5 ± 2.1) mg/L],while its serum IL-10 level was lower than that of the control group[(195.2 ± 33.6) ng/L vs (458.5 ± 102.2)ng/L],and there were significant differences between the 2 groups (t =33.26,32.45,10.94,-53.72,all P ＜0.01) ; there were significant differences in terms of IL-6,IL-10 and ICAM-1 level among the mild,the moderate and the severe groups (F =128.90,102.60,8.25,all P ＜0.05).Of which the serum levels of IL-6,ICAM-1 and hsCRP of the severe group[(3.22 0.27) ng/L,(427.7 ± 95.4) μg/L,(21.0 ± 3.9) mg/L] were higher than those of the mild group [(1.92 ± 0.24) ng/L,(236.5 ± 115.6) μg/L,(11.0 ± 3.8) mg/L] and the moderate group [(2.02 ± 0.31) ng/L,(401.5 ± 105.6) μg/L,(17.0 ± 2.8)mg/L],and serum levels of IL-6,ICAM-1 as well as hsCRP were increased accompanied with the raise of AHI.While the serum level of IL-10[(115.2 ±30.6) ng/L] in the severe group was lower than that of the mild and the moderate groups [(400.2 ± 55.6) ng/L,(203.2 ± 27.6) ng/L] ; serum levels of IL-6 and ICAM-1 of OSAHS children were positively correlated with AHI and micro-arousal index (r =0.341,0.427,all P ＜0.05),negatively correlated with lowest oxygen saturation (LSaO2) at night (r =-0.190,P ＜ 0.01),and without correlation with body mass index (BMI) (r =-0.121,P ＞ 0.05).Serum level of IL-10 was negatively correlated with AHI (r =-0.266,P ＜ 0.05),positively correlated with LSaO2 (r =0.240,P ＜ 0.01),and without correlation with BMI or micro-arousal index (r =-0.183,-0.159,all P ＞ 0.05) ; After 12-week treatment,the IL-6 and ICAM-1 levels of OSAHS group [(2.02 ± 0.13)ng/L,(269.9 ± 107.2) μg/L] were decreased,while IL-10 [(476.3 ± 86.t2) ng/L] were increased compared with pre-treatment[(3.08 ± 0.30) ng/L,(187.2 ± 29.63) ng/L,(379.9 ± 105.2) μg/L] (t =24.22,22.32,66.96,all P ＜ 0.05).Conclusions OSAHS children have systemic inflammatory response,which may increase the risk of cardiovascular disease; this inflammatory response is reversible,so early identification and treatment of OSAHS is beneficial.

[Sleep disorders and their influencing factors in primary school children from Urumqi].

OBJECTIVE: To understand the prevalence of sleep disorders and their influencing factors in primary school children from Urumqi. METHODS: A total of 2034 children at the ages of 6-14 years were randomly sampled in 3 districts of Urumqi. The children's sleep states and their family and social environments were investigated through questionnaires. RESULTS: The prevalence of sleep disorders in the subjects was 55%. The prevalence of sleep inquietude was the highest (14.7%), followed by sleep talking (4.8%), sleep walking (1.5%), nocturnal enuresis (1.5%), sleep teeth grinding (5.7%), habitual snoring (12.9%), sleep apnea (0.5%), and waking up by choke (1.9%). Taking drugs to stimulate or inhibit the central nervous system, frequent colds, confined housing area, family history, and sleeping with parents were risk factors for the development of sleep disorders. CONCLUSIONS: The prevalence of sleep disorders within primary school children in Urumqi is higher than the reported data. The development of sleep disorders is multifactorial.